Representative engagement
MultiOmics
MultiOmics is an AI-native precision-diagnostics company focused on early breast-cancer detection.
- Challenge
- An early-stage diagnostics company needed integrated scientific, operating, and corporate strategy to advance its concept and establish a credible development path.
- Strategic Premise
- MultiOmics is pursuing a precision-diagnostics strategy for earlier breast-cancer detection, bringing scientific, business, and AI strategy together around a consequential clinical problem.
- Michael's Role
- Interim CSO/CBO through Attenuated Technologies. Michael leads scientific development, operating coordination, corporate strategy, business-development support, and AI strategy.
- Technology and Execution Context
- Precision diagnostics, early cancer detection, scientific strategy, and AI-enabled research and organizational workflows.
- Outcome
- Selected for the 2025 C10/LabCentral AI-BioHub cohort. Michael created the application and pitch materials used during the program.
Timeline
Current engagement
Integrated scientific and executive leadership
Michael serves as Interim CSO/CBO through Attenuated Technologies.